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ABSTRACT We have used molecular dynamics simulations to investigate the effect of phosphorylation and mutation on the
cytoplasmic domain of phospholamban (PLB), a 52-residue protein that regulates the calcium pump in cardiac muscle.
Simulations were carried out in explicit water systems at 300 K for three peptides spanning the ﬁrst 25 residues of PLB: wild-
type (PLB1–25), PLB1–25 phosphorylated at Ser16 and PLB1–25 with the R9C mutation, which is known to cause human heart
disease. The unphosphorylated peptide maintains a helical conformation from 3 to 15 throughout a 26-ns simulation, in
agreement with spectroscopic data. Comparison with simulations of a fourth peptide truncated at Pro21 showed the importance
of the region from 17 to 21 in preventing local unfolding of the helix. The results suggest that residues 11–16 are more likely to
unfold when speciﬁc capping motifs are not present. It is proposed that protein kinase A exploits the intrinsic ﬂexibility of the 11–
21 region when binding PLB. In agreement with available CD and NMR data, the simulations show a decrease in the helical
content upon phosphorylation. The phosphorylated peptide is characterized by helix spanning residues 3–11, followed by a turn
that optimizes the salt-bridge interaction between the side chains of the phosphorylated Ser-16 and Arg-13. Replacing Arg-9
with Cys results in unfolding of the helix from C9 and an overall decrease of the helical conformation. The simulations show that
initiation of unfolding is due to increased solvent accessibility of the backbone atoms near the smaller Cys. It is proposed that
the loss of inhibitory potency upon Ser-16 phosphorylation or R9C mutation of PLB is due to a similar mechanism, in which the
partial unfolding of the cytoplasmic helix of PLB results in a conformation that interacts with the cytoplasmic domain of the
calcium pump to relieve its inhibition.
INTRODUCTION
The 52-mer protein phospholamban (PLB) regulates calcium
stores by inhibiting the sarcoplasmic reticulum Ca-ATPase
(SERCA), a membrane-bound enzymatic calcium pump that
triggers cardiac relaxation by lowering cytosolic Ca21 con-
centrations. Phosphorylation of PLB relieves the inhibition,
resulting in a return of Ca21 into the sarcoplasmic reticulum
and the start of a new cardiac cycle (MacLennan and Kranias,
2003).
Phospholamban (shown schematically in Fig. 1) regulates
SERCA by binding to both membrane and cytosolic regions
of the enzyme. The transmembrane domain inhibits SERCA
at submicromolar [Ca21], whereas phosphorylation of the
cytoplasmic domain at Ser-16 relieves this inhibition. The
interaction mode has recently been modeled by docking
the NMR-derived structure of PLB (Mortishire-Smith et al.,
1995; Pollesello et al., 1999; Lamberth et al., 2000; Zamoon
et al., 2003) to the x-ray structure of SERCA-1A in its
thapsigargin-bound, calcium-free state (Toyoshima et al.,
2003). According to this model, the transmembrane helix of
PLBﬁts into a groove formed by helicesM2,M4,M6, andM9
of SERCA. In the cytosol, residue K3 of PLB reaches near
residue K400 of SERCA, whereas the loop domain (residues
17–21) interacts with residues in loop 67 of the pump (Asahi
et al., 2000). The model could not clearly deﬁne the inter-
action of domain IA with SERCA because of a poor ﬁt be-
tween SERCA and the NMR-derived structure of PLB in this
region. Satisfactory docking was achieved after unfolding the
domain I helix observed by NMR. It was proposed that un-
folding was a necessary step before phosphorylation at Ser16
by protein kinase A (PKA) (Toyoshima et al., 2003).
Recent studies have suggested that domain IA maintains
a helical structure when bound to SERCA-1A, whereas the
loop domain undergoes conformational changes responsible
for PKA recognition (Chen et al., 2003). The importance
of structural and/or chemical integrity of domain IA for
recognition by the pump is further shown by the effect of
mutations in this region. Mutation of Arg-9 to Cys severely
diminishes PLB inhibitory activity in vitro and blocks wild-
type PLB phosphorylation, resulting in dilated cardiomyop-
athy in dominant phenotypes (Schmitt et al., 2003). An
extensive site-directed mutagenesis study has shown that
region IA is highly sensitive to side-chain replacement, as
single point mutations of 13 out of 20 residues either reduce
or abolish PLB’s inhibitory potency (Toyofuku et al., 1994).
Domain IA of PLB experiences environments of very
different polarities. As an isolated monomer, it lies on the
membrane surface (Mascioni et al., 2002; Zamoon et al.,
2003; Karim et al., 2004), but it is in the cytosol when
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interacting with SERCA (Toyoshima et al., 2003; Kirby
et al., 2004). Experimental studies have shown that the
helical order of domain IA of PLB is highly sensitive to
the chemical environment (Karim et al., 2004), suggesting
that the helix/coil equilibrium of this region is the key for
understanding both the interaction with the pump and its
recognition by PKA. Studies of PLB obtained in low-
polarity media generally agree on the helical structure of
membrane-spanning domain. However, the helical content
of domain IA decreases in polar solvents and upon
phosphorylation. Circular dichroism (CD) spectra of PLB1–
25 show 60% helical content in 30% TFE (Mortishire-Smith
et al., 1998) but only 17% in water (Lockwood et al., 2003).
NMR spectra of PLB1–25 in TFE have shown a shortening
of the domain IA helix down to residues 2–12 upon
phosphorylation (Mortishire-Smith et al., 1995; Pollesello
and Annila, 2002). The structural details of domain IA also
vary with solvent. In TFE, the domain IA helix spans
residues 3–18, followed by a b-III turn from residue 19 to 21
(Pollesello et al., 1999). The domain IA helix is shorter in
a CH4/CHCl3 mixture, spanning residues 4–16, whereas
residues 17–20 form a short hinge before the start of the
domain II helix at Pro-21 (Lamberth et al., 2000). In DPC
micelles, domain IA is helical from residue 2–16, whereas
residues 17–21 form a b-IV turn of ﬁve amino acids,
(Zamoon et al., 2003).
Molecular dynamics (MD) simulations have successfully
studied the relative stability of the helical conformation in
short peptides (Levy et al., 2001; Bystroff and Garde, 2003).
The effect of phosphorylation as a function of sequence
position has been studied using Monte Carlo/stochastic
dynamics simulations (Smart and McCammon, 1999) and
applications of a modiﬁed Lifson-Roig helix-coil model
(Andrew et al., 2002). In this study, we have used simulations
to obtain atomic-level insight into the mechanism of peptide
dynamics of domain I of PLB and the effect of phosphory-
lation and mutation on the helix. The peptides used in the
study were PLB1–25, PLB1–25 phosphorylated at S16 (P16-
PLB1–25), and a mutant in which ARG-9 is replaced with
cysteine (R9C-PLB1–25). Peptides PLB1–25 and P16-PLB1–25
were chosen for comparison with experimental results
(Mortishire-Smith et al., 1995, 1998; Lockwood et al.,
2003). A shorter peptide capped at Pro-21, PLB1–21, was
used to study unfolding from an ideal a-helical conformation
and to rationalize the differences in helical content observed
in various solvents. Comparison of the helical propensity of
wild-type versus the R9C mutant provided a mechanistic




Simulations were carried out using the GROMACS 3.1.4 package (Lindhal
et al., 2001) with the GROMOS96 force ﬁeld (vanGunsteren et al., 1996) and
the simple point charge (SPC) water model (Berendsen et al., 1981). The
simulation protocol consisted of immersing the solute into an equilibrated
water box containing 4927 water molecules and applying periodic boundary
conditions. Long-range electrostatic interactions were calculated using
particle-mesh Ewald (PME). The total charge of the system was set to zero
by adding chlorine ions. Systems were ﬁrst energy-minimized using a
steepest descent algorithm for 1000 steps and a convergence cutoff of 2000
kJ 3 mol1 3 nm1. Equilibration was reached by ﬁrst performing a short
simulation under NVT conditions were positional constraints on the peptide
were gradually lowered from 1000 kJ3mol13 nm2 to zero. Simulations
were then continued under NPT conditions until the indicated time. Tem-
perature and pressure were kept at 300 K and 1 bar, respectively, using the
Berendsen algorithm (Berendsen et al., 1984) with tT ¼ 0.1 and tP ¼ 0.5.
Simulations of PLB1–25 made use of the average NMR structure in
DPC micelles (Zamoon et al., 2003) by removing the additional ﬁrst residue
(Ala in the NMR structure), truncating the peptide at residue 25, and adding
charged N- and C-termini. Therefore, the peptide sequence was identical to
the uncapped peptide examined by CD (Mortishire-Smith et al., 1995). For
simulations of R9C- and P16-PLB1–25, the Arg-9 and Ser-16 side chains
were replaced with Cys and phosphoserine, respectively. Phosphoserine
parameters were used as provided by the GROMOS96 force ﬁeld. The
starting conformation of PLB1–21 was an ideal a-helix (f ¼ 65, c ¼
40), capped at the C-end with an N9-methyl group.
Analyses of the MD trajectories were performed using the utilities of the
GROMACS software package (Lindhal et al., 2001). Hydrogen bonds were
computed using a 2.5 A˚ distance cutoff (hydrogen-acceptor distance) and




Simulations used the average NMR structure observed in
DPC micelles (Zamoon et al., 2003). This structure is an
FIGURE 1 Schematic representation of the PLB sequence. Horizontal
lines denote the membrane boundaries and amino acids are shown in circles
using their one-letter code. The arrow points to the Ser-16 phosphorylation
site. (Domain IA) Short amphiphilic helix (residues 2–16). (Loop domain)
Hinge region (residues 17–21). (Domain IB) Hydrophilic residues of the
transmembrane helix. (Domain II) Hydrophobic residues of the trans-
membrane helix (residues 31–52). Domain boundaries are deﬁned as in
Metcalfe et al. (2004).
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a-helix from residue 2–16, followed by b-IV type turn from
17 to 21. Residues 22–25 form the beginning of the domain
IB helix. The NMR structure is characterized by several side
chain-side chain and side chain-backbone hydrogen bonds.
These occur between the side chains of R9 and both E2 and
Q5, between S10 and R13, and between the backbone atoms
of T8 and A10 with the side chains of V4 and R14, respec-
tively. In region IB, the side chains of residues Q22, Q23,
and R25 hydrogen bond to those of R13, R14, and E19,
respectively.
During simulations, the peptide structure departs from
the NMR-based structure (Fig. 2 A), largely because of
unfolding of the C-terminal 22–25 region. Residues 3–15 are
in a helical conformation ;70% of the time, giving an
overall helicity close to 40%, as calculated from the last
23 ns of the MD trajectory (Fig. 3 A). The backbone dihedral
angles of T17, M20, and P21 conﬁne to similar regions of
the Ramachandran plot as the NMR structures (Zamoon
et al., 2003) (Fig. 4). The largest changes occur for Ile-18
and Glu-19, and consist mainly of a 180 ﬂip of the peptide
plane between these two residues. The conformational
change gives rise to new hydrophobic interactions between
the side chains of A15, I18, and M20 (Fig. 5 A). These three
residues form a hydrophobic cap that connects to the
hydrophobic face of the a-helix spanning residues 3–15. The
carboxyl and amide groups of A15, I18, and M20 cluster
together with the side chains of S16, T17, and E19 and
produce a polar face which connects to the hydrophilic face
of the a-helix.
Hydrogen bond contributions from sidechains of residues
in the a-helix are negligible throughout the 26-ns trajectory.
In particular, hydrogen bonds between Arg-9 and neighbor-
ing residues, such as with Glu-2 and Gln-5, are present in 6%
of the trajectory. Hydrogen bonds between the polar Thr-8
side chain and the backbone carbonyl of either Val-4 or Gln-
5 occur 5% of the time.
PLB1–21
Simulations started with PLB1–21 in an ideal a-helical
conformation. The helix rapidly unfolds from the C-terminal
end by ;5 residues in the ﬁrst ﬁve ns of simulation (Fig.
2 B). Up to 12 ns residues 11 and 12 are in a helical con-
formation 20% of the time. Plot of total helicity per residue
(Fig. 3 B) shows local unfolding of residues A11 and L12,
whereas region 13–15 remains conﬁned to the a-region 50%
of the time. A snapshot of the simulation at 24 ns (Fig. 5 B)
shows the conformation to be a N-terminal helix up to
residue 10 capped by a turn at residues 11 and 12, followed
by one helical turn from residue 13 to 16.
P16-PLB1–25
Partial unfolding occurs after only 5 ns (Fig. 2 C) from the
C-terminus end up to residue 12. The shorter helix spans
residues 2–;11 and it is stable to 22 ns, followed by further
unfolding to residue R9. Over the last 13 ns of the
simulation, ;35% of the residues are in a helical conforma-
tion 70% of the time, thus giving total helix content of;25%
(Fig. 3 C). The phosphorylated peptide adopts a new
conformation characterized by a salt-bridge between the
phosphoserine and Arg-13 side chains, as shown in Fig. 5 C.
Further unfolding of the helix to residue 9 results in a salt-
bridge of the phosphate with both Arg-13 and Arg-14. The
backbone region from residue 13 to 17 undergoes a confor-
mational switch at ;5 ns characterized by dihedral angles
FIGURE 2 RMS deviation of backbone atoms dur-
ing MD trajectories. (A) PLB1–25; (B) PLB1–21; (C)
P16-PLB1–25; and (D) R9C-PLB1–25.
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change at R13 and S16 from the a- to the b-region of
the Ramachandran plot (Fig. 6). The conformation from R13
to S16 resembles a b-I type turn. The Ca-Ca distance be-
tween these two residues is ,7 A˚ and the f/c angles of
R14 and A15 are in the range of those observed for b-I turns
(Hutchinson and Thornton, 1994). However, the R13
carboxyl and the S16 NH are not hydrogen bonded. The turn
creates hydrophobic interactions between I12 and I18 on one
side and a clustering of the charged residues P-Ser-16, R13,
E19, and R14 on the opposite face of the peptide.
R9C-PLB1–25
Two separate simulations were carried out for a total of 45
ns. The plot of the helicity per residue (Fig. 3 D), averaged
over the two simulations, clearly shows a decrease in the
time spent in the helical conformation compared to the wild-
type peptide (Fig. 3 A). The behavior of the C-terminal
residues from 17 to 25 is similar to that of the wild-type
peptide. The snapshot of the peptide taken at 24 ns (Fig. 5 D)
shows a helix break caused by local unfolding from Cys-9.
DISCUSSION
Comparison with experimental data on
phosphorylation of PLB
CD experiments on PLB1–25 in aqueous solution have shown
the presence of a small amount (;20%) of helical structure
(Mortishire-Smith et al., 1995; Lockwood et al., 2003).
FIGURE 3 Plot of percent time spent in the helical
conformation by each residue in four PLB peptides. (A)
PLB1–25; (B) PLB1–21; (C) P16-PLB1–25; and (D) R9C-
PLB1–25.
FIGURE 4 (f, c) Ramachandran plots of residues in the
C-terminal region of PLB1–25. White circles indicate
values observed in the NMR structure (Zamoon et al.,
2003).
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However, in the presence of 30% TFE, the a-helical
population was 60%, whereas phosphorylation at Ser-16
reduced it to 27% (Mortishire-Smith et al., 1995). Under
similar conditions, NMR structural data on PLB1–25
(Mortishire-Smith et al., 1995) and PLB1–36 (Pollesello and
Annila, 2002) indicated decreased helical content upon
phosphorylation in Ser-16. A ﬂuorescence energy transfer
study suggested a decrease in the width of the distance
distribution between ends of the PLB cytoplasmic domain
upon phosphorylation, but this provided no direct informa-
tion about helical content (Li et al., 2003). In line with the
NMR and CD data, we ﬁnd a decrease in the a-helical
fraction upon phosphorylation. Quantitative comparison of
the helical fraction depends on various factors, such as
intrinsic accuracy of the CD technique (5–10% accuracy
limit, Lockwood, personal communication), the SPC water
model used in this study, and the length of the simulation.
The SPC water model underestimates the bulk dielectric
permittivity by ;20% (van der Spoel et al., 1998). By com-
parison, the dielectric permittivity of a 30% TFE solution is
;60, similar to that of SPC water (van der Spoel et al.,
1998). Simulations conducted using different dielectric
values have shown that the helical fraction increases sixfold
when the dielectric constant changes from 80 to 40 (Vila
et al., 2000). Therefore, the difference between our com-
puted fraction and the experimental results may be explained
by the smaller dielectric permittivity of SPC water compared
to bulk water. The extent of the helical conformation, from
residue 3 to residue 16 for PLB1–25 and from 3 to 10 for
P16-PLB1–25 is also in agreement with the NMR data in TFE
(Mortishire-Smith et al., 1995). The computed trend in
helical content between the wild-type and the phosphory-
lated peptide (;50% reduction) is also quantitatively similar
to that observed ratio. A complete study of the helix-coil
equilibrium of domain IA, sampling both the folded and
unfolded states (Snow et al., 2002) may improve the ac-
curacy of the calculated helical fraction. However, the
agreement with the experimental results suggests that the
simulations are representative of the most populated
structures.
Phosphorylation at Ser-16 decreases the helical content,
but results in a well-deﬁned structure in region 3–17 (Fig. 5
C). The extent of the helix, mainly from residues 3 to 11, is
in good agreement with experiments. The NMR data of
phosphorylated PLB1–36 showed a helical conformation up
to I12 (Pollesello and Annila, 2002), but measured chemical
shifts indicated a loss of helical structure starting at residue
R9. A hydrogen bond was also observed between the
phosphorylated S16 and Arg-13. The MD simulations
shows that when the helix extends to residue 11, the salt-
bridge is between P-Ser-16 and Arg-13, whereas unfolding
to residue 9 allows for interaction of Ser-16 with both Arg-
13 and Arg-14. Steric and ionic interactions between the
phosphate group and R13 and R14 probably drive the
conformational switch from R13 to S16 to optimize the salt-
bridge between S16 and R13. The conformational switch
consists of a movement of residues R13 and P-S16 from the
a- to the b-region of the Ramachandran plot. Backbone
angles of R14 and A15 are characterized by smaller f
values and higher c values than those of a standard helix
(Fig. 6).
A previous study of CD and titration data on model
peptides using a modiﬁed Lifson-Roig theory has shown that
phosphorylation in the helix interior destabilizes the helix
by 1.2 kcal/mol relative to serine (Andrew et al., 2002)
consistent with our conclusion that phosphorylation desta-
bilizes the helix in domain IA of PLB. Thus the effect of PLB
phosphorylation on FRET (Li et al., 2003), decreasing the
range of end-to-end distances in PLB, is probably not due to
an increase in the helical content, but to the creation of a turn
conformation stabilized by the salt-bridge between P-Ser-16
and Arg-13 side chains.
FIGURE 5 Ribbon representation of the PLB peptides. Hydrophobic
residues are shown in orange and polar residues in blue. Proline 21 is shown
in green. (A) Snapshot of PLB1–25 at 20 ns. Residues A15, S16, T17, I18,
and M20 are shown in CPK to illustrate side-chain interactions in the turn
region. (B) Snapshot of PLB1–21 at 24 ns. (C) Snapshot of P16-PLB1–25 at 13
ns, showing hydrogen bond between P-Ser-16 and Arg-13. (D) Snapshot at
24 ns of R9C-PLB1–25.
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Interactions stabilizing the helix
Hydrophobic side-chain interactions at the C-end cap the
helix (Fig. 5 A), thus preventing unfolding. The simulated
structures are characterized by hydrophobic interactions
between the side chains of A15, I18, and M20. This cluster
connects with the nonpolar face formed by V4, A11, and I12
(Fig. 5 A), thus dividing the peptide into two distinct polar
and nonpolar faces. Speciﬁc side chain-side chain hydrogen
bonds between domain IA and the loop domain or domain IB
were not observed, suggesting that local interactions at the
C-cap are sufﬁcient to prevent unfolding from this end. The
conformation of the loop domain differs from the NMR
structure (Zamoon et al., 2003) mainly at residues I18 and
E19, where the peptide plane between these two residues
undergoes a 180 ﬂip. As a result, Met-20 side chain faces
the interior of the loops, although it is exposed to the solvent
in the NMR structure. In contrast to the simulation results,
the NMR-derived structures show that capping is mostly
through backbone hydrogen bonds (Zamoon et al., 2003).
The backbone dihedral angles f and c of residues A15 and
S16 are in the a-helical region of the Ramachandran plot but
have large deviations from the mean values of646 7 and
41 6 7, respectively (Aurora and Rose, 1998). The result
is a tightening of the helix at this end and the carboxyl of
R13 is within hydrogen bond distance of the amide of three
residues, S16, T17, and I18. Therefore, the transition from
the domain IA helix to the loop domain occurs mainly
through these three backbone hydrogen bonds in the NMR
structures in lipid micelles, whereas it is through hydropho-
bic interactions in simulations of the shorter peptide in
aqueous solution.
The sequence of the cytoplasmic domain of PLB
determines its intrinsic helical propensity. In particular, Pro
at position 21 could function as either an N-cap for the
membrane-spanning helix or a C-cap for the domain 1A helix.
The NMR-derived structure shows Pro-21 to be an N-cap,
whereas the preceding three residues (Ile-18 to Met-20) are
unfolded. The MD simulations of PLB1–21 may offer an ex-
planation for the observed structural behavior of this region.
When PLB1–21 is in an ideal a-helical conformation, fraying
occurs up to theThr-17 carboxyl because of themissing amide
hydrogen at Pro-21. This unfolding transition is seen during
the ﬁrst 5 ns of the simulation (Fig. 2 B). Structures between
5 and 11 ns are characterized by partial local unfolding at 11
and 12, whereas residues 13–16 form one helical turn 50% of
the time. The helix break allows the formation of new side
chain-side chain and side chain-main chain hydrogen bonds
that persist throughout the simulations and likely prevent
further unfolding of the N-terminal helix. Such behavior
where fraying from theC-end is followed by the appearance of
kinks and unfolding/refolding of shorter helical spans, is
similar to that observed in previous MD simulations of model
a-helical peptides (Daggett and Levitt, 1992).
Dynamic equilibrium between folded and
unfolded structures
The lack of helical structure from residues 17 to 20 observed
experimentally in all solvents is probably due to fraying from
FIGURE 6 (f, c) Ramachan-
dran plots of residues 11–22 of
P16-PLB1–25.
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Pro-21. Differences in helical content observed in solvents
of different polarities are probably due to differences in the
folding/unfolding equilibrium of shorter helical spans in
the 11–16 region. EPR spectra of PLB in lipid bilayers have
detected two well-resolved conformational states in the
cytoplasmic domain (Karim et al., 2004). A TOAC spin label
at position 11 identiﬁed an ordered component consistent
with a stable a-helical conformation. A second component
indicated nearly isotropic nanosecond disorder, implying
a locally unfolded intermediate, as suggested by the results
of this study. Phosphorylation at S16 shifts the conforma-
tional equilibrium substantially toward the unfolded state
(C. Karim, University of Minesota, personal communication,
2004), again in agreement with simulations (Fig. 3 C).
X-ray structures of model peptides bound to protein
kinases (Johnson et al., 1998) do not show secondary
structure for the six residues preceding the phosphoryla-
tion site. However, the secondary structure of peptides before
phosphorylation may be a poor predictor of the conformation
observed when bound to PKA (Kreegipuu et al., 1998).
Apparently, conformational ﬂexibility may be more impor-
tant than the speciﬁc secondary structure before binding. The
MD simulations show that the C-terminus of the domain A is
more likely to unfold if capping interactions are not present
to stabilize the domain 1A helix after fraying from Pro-21. It
is likely that PKA takes advantage of the intrinsic ﬂexibility
in the 11–16 region for molecular recognition. Local
unfolding may also facilitate interaction of the N-terminal
helical region with SERCA, as ﬁrst suggested by Toyoshima
et al. (2003). In their docking study, Arg-13 and Arg-14
unwind from the helical conformation, are exposed to
solvent, and are available for PKA binding. This model is
supported experimentally by EPR and NMR data showing
that SERCA binds preferentially to an extended conforma-
tion of PLB in which the cytoplasmic domain is partially
unfolded (Kirby et al., 2004; Zamoon et al., 2005). It is
probably this partially unfolded conformation of PLB,
stabilized by phosphorylation that binds to the cytoplasmic
domain of SERCA and relieves the inhibition caused by the
transmembrane domain.
The R9C-mutation
Simulations of R9C-PLB1–25 show decreased helicity with
respect to the wild-type peptide (Fig. 3). The loss of helical
conformation is caused by an initial local distortion near Cys-
9, already observed during the ﬁrst 100 ps of simulations, as
shown in the snapshot in Fig. 7. The distortion then gives rise
to a helix break and further unfolding from C9 to both ends.
Mutation ofArg toCys replaces a large and charged side chain
with one that is smaller and hydrophobic. Possible effects due
to side-chain replacement are changes in the electrostatic
interactions with the other side chains, changes in the side-
chain packing, and changes in water accessibility. Previous
studies (Vila et al., 2000; Garcia and Sanbonmatsu, 2002)
have shown that large polar side chains restrict solvent
accessibility of the backbone atoms of nearby residues, thus
favoring helix stabilization, whereas the opposite is true for
smaller side chains.
The comparison of the accessibility area between R9C and
wild-type peptide explains how the R9C mutation decreases
the helical propensity. Atomic accessibility areas were
calculated for backbone atoms (N-Ca-C-O) and averaged
over the ﬁrst 100 ps of the simulations (Fig. 8). In PLB1–25,
the lowest values are observed at Arg-9 and Arg-13, whereas
the largest values are observed for the smallest side chains,
Ser-10 and Ala-11. The R9C mutant peptide, on the other
hand, shows increased accessibility at Cys-9, due to its
smaller side chain. In addition, the accessibility of Gln-5 has
also increased. Inspection of Fig. 7 shows a weakening of the
backbone hydrogen bond between Cys-9 and Gln-5 due to
increased water accessibility with water competing with the
FIGURE 7 Snapshots of PLB1–25 and R9C-PLB1–25 taken at 100 ps.
Atoms of residues 5–9 are colored by CPK; all others are colored green. (A)
Shielding of backbone atoms of Gln-5 by the Arg-9 side chain. (B) Solvation
of Gln-5 backbone after replacement of Arg-9 with Cys.
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intrachain hydrogen bonds of the a-helix. An additional
increase in accessibility is also seen at Ser-10 and Ala-11.
Accessibility of Tyr-6 backbone is smaller than in PLB1–25,
due to the proximity of its Ca atom to the sulfur atom of Cys-
9. Overall, mutation to a smaller side chain at position 9
affects the accessibility of the backbone atoms at positions
5, 6, 10, and 11. The smaller Cys side chain allows local
opening because of increased competition for hydrogen
bonding between water and backbone donors. Water
accessibility to R9C-PLB could also affect the helical
structure of the monomeric protein lying on the membrane
surface. NMR-derived proton/deuterium exchange factors in
lipid micelles show that Arg-9 is exposed to the bulk water
(Zamoon et al., 2003).
The simulation results of R9C-PLB1–25 suggest that the
loss of inhibitory activity observed for the R9C mutant in
vitro (Schmitt et al., 2003) is not due to the loss of speciﬁc
interactions between Arg-9 on PLB and SERCA, but to an
overall change in the shape and dynamics of region IA,
producing a partially unfolded structure that mimics phos-
phorylated PLB and thus relieves SERCA inhibition.
CONCLUSIONS
We have used MD simulations to study the effect of
phosphorylation and mutation on the helical conformation of
the cytoplasmic region of phospholamban. The results
satisfactorily reproduce the behavior of the wild-type and
phosphorylated peptides previously observed by CD and
NMR. The results further show that the degree of unfolding
of helix IA from the C terminus depends upon fraying from
Pro-21 and subsequent formation of capping motifs. Local
unfolded intermediates, from residue 11 to residue 16, are
observed when capping interactions are not present. We
propose that phosphorylation at Ser-16 by PKA is facilitated
by the intrinsic higher ﬂexibility of the peptide in the 11–16
region. The phosphorylated peptide is characterized by
a shortened helix, containing a salt-bridge between the
phosphorylated Ser-16 and Arg-13. The region from residues
3 to 11 remains in the helical conformation after phosphor-
ylation. Mutation of Arg-9 to cysteine increases the solvent
accessibility of backbone atoms in neighboring residues thus
weakening the backbone hydrogen bond between position 9
and position 5, because of competition with the surrounding
water molecules. The local distortion functions as a nucle-
ation site for the unfolding of the helix. We propose that the
loss of inhibitory PLB potency is due to a similar molecular
mechanism for both S16 phosphorylation and the R9C
mutation: reduced helical stability in domain 1A of PLB
produces a more dynamic conformational state, which inter-
acts with SERCA to relieve its inhibition.
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